Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8609294 | 0.89 | LTA4H (0.53) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL4464939 | 0.88 | GAA (0.59) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL19102485 | 0.86 | GAA (0.52) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL13756031 | 0.86 | GAA (0.56) | GAAMGAMSIMGAM2LTA4H | |
| Hydrochloric Acid SCHEMBL11851530 | 0.86 | GAA (0.56) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL1398380 | 0.84 | TSHR (0.52) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL23152728 | 0.83 | LTA4H (0.40) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL5032610 | 0.83 | ALDH1A1 (0.46) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL10306173 | 0.83 | GAA (0.45) | GAAMGAMSIMGAM2LTA4H | |
| SCHEMBL8609835 | 0.82 | LTA4H (0.49) | GAAMGAMSIMGAM2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-3892621-B1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2024-09-18 | — | — | EP | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| CN-115996927-A | Pyrimido [5,4-d ] pyrimidine derivatives and combinations with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-111434662-B | Haloallylamine compound and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-4110784-A1 | PYRIMIDO[5,4-D]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | TransThera Sciences (Nanjing), Inc (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3892621-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892621-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| CN-111434662-A | Haloallylamine compound and application thereof | 南京药捷安康生物科技有限公司 | 2020-07-21 | — | — | CN | disclosed |
| WO-2020143763-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | 南京药捷安康生物科技有限公司 | 2020-07-16 | — | — | WO | disclosed |
| US-7671087-B2 | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof | SEPRACOR INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090163593-A1 | AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-06-25 | — | — | US | disclosed |
| US-7511073-B2 | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof | SEPRACOR, INC. (US) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371432-B2 | Haloallylamine compounds and application thereof | ADRA1D, ADRA1A, VAPA | GAA 2675/4885MGAM 3943/4885SI 4741/4885 |
| US-20220081439-A1 | HALOALLYLAMINE COMPOUNDS AND APPLICATION THEREOF | ADRA1D, ADRA1A, VAPA | GAA 2675/4885MGAM 3943/4885SI 4741/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | GAA 2491/4885MGAM 4524/4885SI 2718/4885 |
| US-20090163593-A1 | AMINES THAT INHIBIT A MAMMALIAN ANANDAMIDE TRANSPORTER, AND METHODS OF USE THEREOF | SLC6A2, HTR2A, SLC18A1 | GAA 518/4885MGAM 2651/4885SI 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.